Sms Pharmaceuticals Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is RIZATRIPTAN BENZOATE, with a corresponding US DMF Number 23066.
Remarkably, this DMF maintains an Active status since its submission on August 26, 2009, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of October 18, 2013, and payment made on May 24, 2013, indicating their dedication to facilitating drug approvals, Categorized as Type II